Looking Ahead
Experts emphasize that the actual risk in this case is low. Most patients who took affected batches are unlikely to experience harm. Long-term risk remains theoretical and minimal.
However, the situation highlights the importance of continued vigilance in pharmaceutical safety. It is a shared responsibility between manufacturers, regulators, and patients.
